[1] Baldwin P.; Ohman A. W.; Tangutoori S.; Dinulescu D. M.; Sridhar S.; Baldwin P.; Ohman A. W.; Tangutoori S.; Dinulescu D. M.; Sridhar S.Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int. [J]. Nanomed. 2018, 13, 8063-8074. [2] Belz J. E.; Kumar R.; Baldwin P.; Ojo N. C.; Leal A. S.; Royce D. B.; Zhang D.; van de Ven, A. L.; Liby, K. T.; Sridhar, S.; Belz, J. E.; Kumar, R.; Baldwin, P.; Ojo, N. C.; Leal, A. S.; Royce, D. B.; Zhang, D.; van de Ven, A. L.; Liby, K. T.; Sridhar, S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics 2017, 7, 4340-4349. [3] Chen L. M.; Yang P. P.; Al Haq, A. T.; Hwang, P. A.; Lai, Y. C.; Weng, Y. S.; Chen, M. A.; Hsu, H. L.; Chen, L. M.; Yang, P. P.; Al Haq, A. T.; Hwang, P. A.; Lai, Y. C.; Weng, Y. S.; Chen, M. A.; Hsu, H. L. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. [J]. Biomed. Sci. 2022, 29, 70. [4] Du C.; Qi Y.; Zhang Y.; Wang Y.; Zhao X.; Min H.; Han X.; Lang J.; Qin H.; Shi Q.; Zhang Z.; Tian X.; Anderson G. J.; Zhao Y.; Nie G.; Yang Y.; Du C.; Qi Y.; Zhang Y.; Wang Y.; Zhao X.; Min H.; Han X.; Lang J.; Qin H.; Shi Q.; Zhang Z.; Tian X.; Anderson G. J.; Zhao Y.; Nie G.; Yang Y.Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. ACS Nano 2018, 12, 10785-10796. [5] Wang Y.; Zheng K.; Huang Y.; Xiong H.; Su J.; Chen R.; Zou Y.; Wang Y.; Zheng K.; Huang Y.; Xiong H.; Su J.; Chen R.; Zou Y.PARP inhibitors in gastric cancer: beacon of hope. [J]. Exp. Clin. Cancer Res. 2021, 40, 211. [6] Wu M.; Liu J.; Hu C.; Li D.; Yang J.; Wu Z.; Yang L.; Chen Y.; Fu S.; Wu J.; Wu M.; Liu J.; Hu C.; Li D.; Yang J.; Wu Z.; Yang L.; Chen Y.; Fu S.; Wu J.Olaparib nanoparticles potentiated radiosensitization effects on lung cancer. Int. [J]. Nanomed. 2018, 13, 8461-8472. [7] Xie H.; Wang W.; Xia B.; Jin W.; Lou G.; Xie H.; Wang W.; Xia B.; Jin W.; Lou G.Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed. Pharmacother. 2020, 127, 110204. [8] Yuan Z.; Chen J.; Li W.; Li D.; Chen C.; Gao C.; Jiang Y.PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert. Opin. Ther. Pat. 2017, 27, 363-382. [9] Zhang D.; Baldwin P.; Leal A. S.; Carapellucci S.; Sridhar S.; Liby K. T.; Zhang D.; Baldwin P.; Leal A. S.; Carapellucci S.; Sridhar S.; Liby K. T.A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics 2019, 9, 6224-6238. [10] Pathade A. D.; Kommineni N.; Bulbake U.; Thummar M. M.; Samanthula G.; Khan W.; Pathade A. D.; Kommineni N.; Bulbake U.; Thummar M. M.; Samanthula G.; Khan W.Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib AAPS. PharmSciTech 2019, 20, 276. [11] Erol K.; Kose K.; Uzun L.; Say R.; Denizli A.; Erol K.; Kose K.; Uzun L.; Say R.; Denizli A.Polyethyleneimine assisted-two-step polymerization to develop surface imprinted cryogels for lysozyme purification. Colloids Surf. B Biointerfaces 2016, 146, 567-576. [12] Fu Z.; Mao Y.; Li S.; Liu S.; Shao C.; Shang P.; Li Q.; Wu C.; Fu Z.; Mao Y.; Li S.; Liu S.; Shao C.; Shang P.; Li Q.; Wu C.Preparation and characterization of ABS and copper (II) sulfate coordination composites by planetary ball mill. Polym. Bulletin 2017, 75, 453-468. [13] Hassan I.; Ebaid H.; Alhazza I. M.; Al-Tamimi, J.; Aman, S.; Abdel-Mageed, A. M.; Hassan, I.; Ebaid, H.; Alhazza, I. M.; Al-Tamimi, J.; Aman, S.; Abdel-Mageed, A. M. Copper Mediates Anti-Inflammatory and Antifibrotic Activity of Gleevec in Hepatocellular Carcinoma-Induced Male Rats. Can. [J]. Gastroenterol. Hepatol. 2019, 2019, 9897315. [14] Sargazi S.; Mukhtar M.; Rahdar A.; Barani M.; Pandey S.;Diez-Pascual, A. M.; Sargazi, S.; Mukhtar, M.; Rahdar, A.; Barani, M.; Pandey, S.; Diez-Pascual, A. M. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review. Int. J. Mol. Sci. 2021, 22, 10319. [15] Gong C.; Yu X.; You B.; Wu Y.; Wang R.; Han L.; Wang Y.; Gao S.; Yuan Y.; Gong C.; Yu X.; You B.; Wu Y.; Wang R.; Han L.; Wang Y.; Gao S.; Yuan Y.Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. [J]. Nanobiotechnol. 2020, 18, 92. |